Company Overview and News

Sesen Bio: What Do The Q1 2018 Earnings Foretell?

2h seekingalpha
Eleven Biotherapeutics is a highly promising and an extremely aggressive grower. Company reported promising earnings results and upcoming guidance today.

SGEN / Seattle Genetics, Inc. 8-K (Current Report)


Why Wall Street Analysts Are Mostly Positive on CRISPR

2018-05-18 marketrealist
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CTX001 is an investigational gene editing therapy that utilizes CRISPR/Cas9 technology. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe.

CRISPR Stock Has Seen Soild Growth in the Last 12 Months

2018-05-18 marketrealist
CRISPR Therapeutics has risen 24% between May 11 and May 17. On May 17, CRISPR Therapeutics (CRSP) stock closed at $65.40 and saw 384% growth from its 52-week low of $13.50 on May 31, 2017. On May 14, 2018, CRISPR Therapeutics stock closed at $56.78, which represented ~7.7% growth over the previous close of $52.73 on May 11.

Rounds Report: The Eleven Train Is Increasing Speed Toward Its May 21 Clinical Binary

2018-05-18 seekingalpha
The overall bioscience market rallied strongly today. Many equities under our coverage moved significantly further north.

Eli Lilly Had Good Reason To Spend $1.6B On Armo

2018-05-16 seekingalpha
Last week Eli Lilly (LLY) spent $1.6 billion on to acquire Armo BioSciences (ARMO) at a 66% premium to its previous closing price.

SGEN / Seattle Genetics, Inc. null

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]

Tracking Seth Klarman's Baupost Group Holdings - Q1 2018 Update

2018-05-15 seekingalpha
The portfolio continues to be heavily concentrated, with the top three positions accounting for one-third of the 13F portfolio.

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

2018-05-11 seekingalpha
Alpine is leveraging on its stellar therapeutic innovation platforms (TIP and vIgD) to deliver the next-generation immuno-oncology (I-O) therapeutics.

Genmab's (GNMSF) CEO Jan van de Winkel on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, and welcome to the Genmab Q1 Reports 2018 Conference Call. Today’s conference is being recorded. During this telephone conference, you may be presented with forward-looking statements that includes words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delays or unsuccessful development projects. Genmab is not under an obligation to update statements regarding the future or to confirm such statements in relation to actual results unless this is required by law.

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

2018-05-07 seekingalpha
The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.

Institutional Top Ideas Series: Orbimed Advisors

2018-05-04 seekingalpha
Today's fund in the spotlight, Orbimed Advisors, is quite large and in the midst of a leadership transition. They avoid outsized bets (over 5% weighting) yet still post decent returns.

SGEN / Seattle Genetics, Inc. / Baker Brothers Advisors LP - SC 13D/A (Activist Investment)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No

SGEN / Seattle Genetics, Inc. / Baker Brothers Advisors LP - SC 13D/A (Activist Investment)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

2018-05-01 seekingalpha
I remind readers that I am not a market timer, as I have no edge in making predictions.

Related Articles

SQ: Square Analysis and Research Report

7h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

TROV: TrovaGene Analysis and Research Report

8h - Asif

BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

CUSIP: 812578102